Tesofensine is a triple monoamine reuptake inhibitor — it raises noradrenaline, dopamine and serotonin. That is a fundamentally different mechanism from the incretin (GLP-1/GIP) peptides. It is a small molecule, not a peptide agonist, and is not approved as a medicine anywhere.
Early-phase studies reported appetite suppression and weight reduction, which is why interest surged alongside the GLP-1 wave. But the mechanism (central adrenergic/monoaminergic stimulation) is closer to older appetite suppressants than to the incretin peptides.
Because Tesofensine adds sympathetic/adrenergic drive, combining it with a GLP-1 or any stimulant can produce additive cardiovascular effects (elevated heart rate and blood pressure) and CNS effects (insomnia, anxiety, irritability), with no published human safety data for those combinations. Our stacking guide flags Tesofensine + GLP-1 and Tesofensine + Retatrutide as combinations to avoid.
| Tesofensine | GLP-1 peptides | |
|---|---|---|
| Type | Small-molecule reuptake inhibitor | Peptide receptor agonists |
| Mechanism | Noradrenaline / dopamine / serotonin | Incretin (GLP-1 ± GIP/glucagon) |
| Main caution | Cardiovascular / CNS stimulation | Gastrointestinal (nausea) |
Tesofensine is tracked on PepsTracker across vendors, normalized to cost-per-mg. For the incretin alternatives, see best peptides for fat loss.
No. Tesofensine is a triple monoamine reuptake inhibitor (noradrenaline, dopamine, serotonin), a completely different mechanism from GLP-1 receptor agonists.
It carries meaningful caution. Tesofensine adds adrenergic stimulation on top of a GLP-1, which can produce additive cardiovascular and CNS effects with no published human safety data for the combination. Most guidance treats it as a combination to avoid.
No. Tesofensine has not received market authorization as a medicine in the US, EU or most other countries and is sold for research use only.